Literature DB >> 20696832

Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Michele D Spring1, Kiprotich Chelimo, Daniel J Tisch, Peter Odada Sumba, Rosemary Rochford, Carole A Long, James W Kazura, Ann M Moormann.   

Abstract

Cross-sectional seroepidemiological studies of populations naturally exposed to Plasmodium falciparum suggest an association between protection from malaria and circulating antibodies to the carboxyl terminus of merozoite surface protein 1 (MSP1). Questions remain regarding the significance of cell-mediated immunity to MSP1 in conferring protection and inducing immunologic memory. Vaccine constructs have been based on the 42-kDa recombinant MSP1 protein (MSP1(42)), which includes the 19-kDa (MSP1(19)) and 33-kDa (MSP1(33)) fragments containing the major B- and T-cell epitopes, respectively. To evaluate T-cell responses to the MSP1(33) fragment, two libraries of overlapping 18-mer peptides from the 3D7 and FVO MSP1(33) regions were used to screen a cohort of asymptomatic Kenyan adults. Gamma interferon (IFN-γ) measured by enzyme-linked immunospot assay (ELISPOT) at multiple time points assessed the magnitude and stability of these responses. The percentage of individuals with IFN-γ responses to single MSP1(33) peptides ranged from nil to 24%, were clustered among a subset of peptides, and were not consistently recalled over time. In comparison to peptide responses, IFN-γ ELISPOT responses to recombinant MSP1(42) were more prevalent, more frequently elicited by the 3D7 as opposed to the FVO allele, and more stable over time. The prevailing MSP1(33) genotype infection was 3D7, with few mixed infections and no sole FVO infections. This study demonstrates that immunity against MSP1(33) after cumulative natural infections consists of low-magnitude and difficult-to-detect IFN-γ responses. Although immunity against MSP1 alone will not confer protection against malaria, demonstrating a relative and sustained increase in T-cell immunity to MSP1 after vaccination would be a reasonable measurement of vaccine responsiveness.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696832      PMCID: PMC2950343          DOI: 10.1128/IAI.00415-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

Review 1.  Towards a blood-stage vaccine for malaria: are we following all the leads?

Authors:  M F Good
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

2.  Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project.

Authors:  O H Branch; A J Oloo; B L Nahlen; D Kaslow; A A Lal
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.

Authors:  Sanjai Kumar; Francois Villinger; Miranda Oakley; Joao C Aguiar; Trevor R Jones; Richard C Hedstrom; Kalpana Gowda; John Chute; Anthony Stowers; David C Kaslow; Elaine K Thomas; John Tine; Dennis Klinman; Stephen L Hoffman; Walter W Weiss
Journal:  Immunol Lett       Date:  2002-04-01       Impact factor: 3.685

4.  Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

Authors:  José A Stoute; Joash Gombe; Mark R Withers; Joram Siangla; Denise McKinney; Melanie Onyango; James F Cummings; Jessica Milman; Kathryn Tucker; Lorraine Soisson; V Ann Stewart; Jeffrey A Lyon; Evelina Angov; Amanda Leach; Joe Cohen; Kent E Kester; Christian F Ockenhouse; Carolyn A Holland; Carter L Diggs; Janet Wittes; D Gray Heppner
Journal:  Vaccine       Date:  2005-12-07       Impact factor: 3.641

5.  Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria.

Authors:  Edwin A M Lee; Dupeh R Palmer; Katie L Flanagan; William H H Reece; Kennedy Odhiambo; Kevin Marsh; Margaret Pinder; Michael B Gravenor; Wendy A Keitel; Kent E Kester; Carter Diggs; David Kaslow; V Apostolopoulos; W Ripley Ballou; Adrian V S Hill; Urszula Krzych; Magdalena Plebanski
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

Review 6.  Progress and challenges for malaria vaccines.

Authors:  Thomas L Richie; Allan Saul
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

Review 7.  The pathogenic basis of malaria.

Authors:  Louis H Miller; Dror I Baruch; Kevin Marsh; Ogobara K Doumbo
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

8.  Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria.

Authors:  Jiraprapa Wipasa; Chakrit Hirunpetcharat; Yuvadee Mahakunkijcharoen; Huji Xu; Salenna Elliott; Michael F Good
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.

Authors:  Niklas Ahlborg; Irene T Ling; Wendy Howard; Anthony A Holder; Eleanor M Riley
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

10.  Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.

Authors:  R A O'Donnell; T F de Koning-Ward; R A Burt; M Bockarie; J C Reeder; A F Cowman; B S Crabb
Journal:  J Exp Med       Date:  2001-06-18       Impact factor: 14.307

View more
  8 in total

1.  Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity.

Authors:  Natalie M Bowman; Jonathan J Juliano; Cynthia J Snider; Oksana Kharabora; Steven R Meshnick; John Vulule; Chandy C John; Ann M Moormann
Journal:  Am J Trop Med Hyg       Date:  2016-08-01       Impact factor: 2.345

2.  Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Authors:  Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

3.  Inhibitory humoral responses to the Plasmodium falciparum vaccine candidate EBA-175 are independent of the erythrocyte invasion pathway.

Authors:  Aida S Badiane; Amy K Bei; Ambroise D Ahouidi; Saurabh D Patel; Nichole Salinas; Daouda Ndiaye; Ousmane Sarr; Omar Ndir; Niraj H Tolia; Souleymane Mboup; Manoj T Duraisingh
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

4.  Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1.

Authors:  Kiprotich Chelimo; Paula B Embury; Peter Odada Sumba; John Vulule; Ayub V Ofulla; Carole Long; James W Kazura; Ann M Moormann
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

5.  Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Authors:  Daniel Dodoo; Michael R Hollingdale; Dorothy Anum; Kwadwo A Koram; Ben Gyan; Bartholomew D Akanmori; Josephine Ocran; Susan Adu-Amankwah; Harini Geneshan; Esteban Abot; Jennylyn Legano; Glenna Banania; Renato Sayo; Donald Brambilla; Sanjai Kumar; Denise L Doolan; William O Rogers; Judith Epstein; Thomas L Richie; Martha Sedegah
Journal:  Malar J       Date:  2011-06-20       Impact factor: 2.979

6.  Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.

Authors:  Dorothy Anum; Kwadwo A Kusi; Harini Ganeshan; Michael R Hollingdale; Michael F Ofori; Kwadwo A Koram; Ben A Gyan; Susan Adu-Amankwah; Edem Badji; Jun Huang; Maria Belmonte; Glenna J Banania; Theophilus B Kwofie; Eileen Villasante; Daniel Dodoo; Martha Sedegah
Journal:  Malar J       Date:  2015-01-21       Impact factor: 2.979

7.  Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Ryan M Mease; Evelina Angov
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

8.  A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.

Authors:  Damien R Drew; Danny W Wilson; Salenna R Elliott; Nadia Cross; Ulrich Terheggen; Anthony N Hodder; Peter M Siba; Kiprotich Chelimo; Arlene E Dent; James W Kazura; Ivo Mueller; James G Beeson
Journal:  BMC Med       Date:  2016-09-23       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.